Merck终止了针对价格纠纷购买革命药品的谈判, Merck ended talks to buy Revolution Medicines over price disputes, despite the $28B–$32B deal’s potential.

根据华尔街日报(Wall Street Journal)报导, Merck因在价格上的分歧, 终止了购买生物技术公司革命药品的谈判, Merck has reportedly ended talks to acquire biotech firm Revolution Medicines, a developer of cancer therapies, due to disagreements over price, according to the Wall Street Journal. 这笔价值在280亿至320亿美元的潜在交易本可以让Merck获得革命实验药物Dalaxonrasib,该试验处于后期试验阶段,具有林业发展局的快车道地位。 The potential deal, valued between $28 billion and $32 billion, would have given Merck access to Revolution’s experimental drug daraxonrasib, which is in late-stage trials and has FDA fast-track status. 革命的市场上限约为227亿美元,它仍然是一个潜在目标,但Merck没有确认停止,也没有发表正式声明。 Revolution, with a market cap of about $22.7 billion, remains a potential target, but Merck has not confirmed the halt, and no official statement has been issued.